{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-298551","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2025-11-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.545016+00:00","generated_at":"2026-05-16T16:33:02.135121+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nuvation Bio discontinues NUV-1511 DDC program; redirects $100-150M to pipeline","bullets":["Discontinued NUV-1511 due to inconsistent efficacy across cohorts; DDC platform continues.","Projected $100-150M in R&D/CMC costs through 2029 reallocated to other pipeline molecules.","First patient enrolled in part 2 of G203 study of safusidenib for IDH1-mutant glioma.","Continued investment in IBTROZI (taletrectinib) commercial launch and TRUST-IV adjuvant study."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-298551","json":"https://secwatch.observer/filing/0001193125-25-298551.json","markdown":"https://secwatch.observer/filing/0001193125-25-298551.md","text":"https://secwatch.observer/filing/0001193125-25-298551.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525298551/0001193125-25-298551-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525298551/d82457d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T16:33:02.135121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}